Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (10124)	7/1/2007 11:18:54 PM
From: Robohogs	Respond to of 10280

I have read some stuff elsewhere and it supposed to be pretty big. And it is not like Sanofi can't sell a sleep drug and they do have extra sales folks with nothing to do given the recent Accomplia news and Ambien generic. Jon

To: tuck who wrote (10124)	7/2/2007 8:54:51 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 10280

but, but, but..... remember, Sepracor has already had a serotonin antagonist in development and dropped it??..... acadia-pharm.com and, if you like the program? Arena is in phase II with their own 2A inverse agonist. edit: SEPR owns a chunk of ACAD, and thus has a small piece of their program.